Two Sigma Investments LP Lowers Stake in Repligen Co. (NASDAQ:RGEN)

Two Sigma Investments LP reduced its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 17.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 359,039 shares of the biotechnology company's stock after selling 77,124 shares during the quarter. Two Sigma Investments LP owned approximately 0.64% of Repligen worth $51,680,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Price T Rowe Associates Inc. MD increased its stake in Repligen by 11.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock worth $1,027,165,000 after buying an additional 743,815 shares in the last quarter. Point72 Asset Management L.P. grew its position in shares of Repligen by 183.1% during the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock worth $132,227,000 after purchasing an additional 594,189 shares in the last quarter. Groupama Asset Managment grew its position in shares of Repligen by 12,321.0% during the fourth quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock worth $58,142,000 after purchasing an additional 400,680 shares in the last quarter. Alyeska Investment Group L.P. bought a new stake in Repligen during the 4th quarter valued at approximately $53,428,000. Finally, Raymond James Financial Inc. purchased a new position in Repligen in the 4th quarter worth approximately $52,492,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Trading Down 0.2%

Shares of NASDAQ RGEN opened at $126.19 on Tuesday. Repligen Co. has a 1-year low of $102.97 and a 1-year high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The business's 50 day moving average is $132.36 and its two-hundred day moving average is $145.11. The stock has a market capitalization of $7.09 billion, a P/E ratio of -247.43, a PEG ratio of 4.54 and a beta of 1.21.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. During the same quarter in the previous year, the business earned $0.28 EPS. The company's quarterly revenue was up 10.4% on a year-over-year basis. As a group, research analysts expect that Repligen Co. will post 1.72 EPS for the current year.

Insiders Place Their Bets

In other news, Director Margaret Pax acquired 250 shares of the firm's stock in a transaction on Monday, March 17th. The stock was acquired at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

RGEN has been the subject of a number of research analyst reports. TD Cowen began coverage on shares of Repligen in a report on Monday, February 10th. They set a "buy" rating and a $200.00 price objective for the company. StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a research note on Thursday, May 8th. Royal Bank of Canada decreased their price target on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 30th. Evercore ISI initiated coverage on shares of Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price objective for the company. Finally, JPMorgan Chase & Co. reduced their target price on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $173.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.